1. Home
  2. TVTX vs EFSC Comparison

TVTX vs EFSC Comparison

Compare TVTX & EFSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TVTX
  • EFSC
  • Stock Information
  • Founded
  • TVTX 2008
  • EFSC 1988
  • Country
  • TVTX United States
  • EFSC United States
  • Employees
  • TVTX N/A
  • EFSC N/A
  • Industry
  • TVTX Biotechnology: Pharmaceutical Preparations
  • EFSC Major Banks
  • Sector
  • TVTX Health Care
  • EFSC Finance
  • Exchange
  • TVTX Nasdaq
  • EFSC Nasdaq
  • Market Cap
  • TVTX 2.5B
  • EFSC 2.2B
  • IPO Year
  • TVTX N/A
  • EFSC 1999
  • Fundamental
  • Price
  • TVTX $29.05
  • EFSC $55.39
  • Analyst Decision
  • TVTX Strong Buy
  • EFSC Buy
  • Analyst Count
  • TVTX 15
  • EFSC 4
  • Target Price
  • TVTX $34.86
  • EFSC $64.25
  • AVG Volume (30 Days)
  • TVTX 1.8M
  • EFSC 161.4K
  • Earning Date
  • TVTX 10-30-2025
  • EFSC 10-27-2025
  • Dividend Yield
  • TVTX N/A
  • EFSC 2.24%
  • EPS Growth
  • TVTX N/A
  • EFSC 15.35
  • EPS
  • TVTX N/A
  • EFSC 5.26
  • Revenue
  • TVTX $333,865,000.00
  • EFSC $637,581,000.00
  • Revenue This Year
  • TVTX $83.23
  • EFSC $18.09
  • Revenue Next Year
  • TVTX $41.49
  • EFSC $4.18
  • P/E Ratio
  • TVTX N/A
  • EFSC $10.53
  • Revenue Growth
  • TVTX 87.94
  • EFSC 9.46
  • 52 Week Low
  • TVTX $12.91
  • EFSC $45.22
  • 52 Week High
  • TVTX $28.85
  • EFSC $63.13
  • Technical
  • Relative Strength Index (RSI)
  • TVTX 73.62
  • EFSC 44.80
  • Support Level
  • TVTX $26.79
  • EFSC $54.34
  • Resistance Level
  • TVTX $28.24
  • EFSC $55.44
  • Average True Range (ATR)
  • TVTX 1.02
  • EFSC 1.57
  • MACD
  • TVTX -0.01
  • EFSC -0.01
  • Stochastic Oscillator
  • TVTX 100.00
  • EFSC 45.90

About TVTX Travere Therapeutics Inc.

Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.

About EFSC Enterprise Financial Services Corporation

Enterprise Financial Services Corporation is a financial holding company. It offers banking and wealth management services to individuals and business customers located in Arizona, California, Florida, Kansas, Missouri, Nevada, and New Mexico, in addition to loan and deposit production offices throughout the United States. The company offers a broad range of business and personal banking services including wealth management services. Lending services include commercial and industrial, commercial real estate, real estate construction and development, residential real estate and consumer loans.

Share on Social Networks: